Q04206 (TF65_HUMAN) Homo sapiens (Human)
Transcription factor p65 UniProtKBInterProSTRINGInteractive Modelling
551 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3; Isoform 4; ) Identical sequences: Gorilla gorilla gorilla: G3SHV6
It is possible new templates exist for this target since these models were created.
Sequence Alignments
Experimental structures
| Description | Oligo-state | Ligands | Structure | Range |
|---|---|---|---|---|
| I-KAPPA-B-ALPHA/NF-KAPPA-B COMPLEX |
Heteromer P19838; P25963; | 1nfi | ||
| Assess | ||||
| Crystal Structure of NFkB, IRF7, IRF3 bound to the interferon-b enhancer |
Heteromer P19838; Q14653; Q92985; | 2o61 | ||
| Assess | ||||
| Crystal structure of a higher-order complex of p50:RelA bound to the HIV-1 LTR |
Heteromer P19838; | 3gut | ||
| Assess | ||||
| NMR structure of the complex between the KIX domain of CBP and the transactivation domain 1 of p65 |
Heteromer P45481; | 5u4k | ||
| Assess | ||||
| NMR structure of the complex between the PH domain of the Tfb1 subunit from TFIIH and the transacti… |
Heteromer P32776; | 5urn | ||
| Assess | ||||
| solution structures of BRD4 second bromodomain with NF-kB-K310ac peptide |
Heteromer O60885; | 2lsp | ||
| Assess | ||||
| 14-3-3 sigma with RelA/p65 binding site pS45 in complex with DP005 |
Heteromer P31947; | 2×CL; 2×0V4; | 6nv2 | |
| Assess | ||||
| 14-3-3 sigma with RelA/p65 binding site pS45 |
Heteromer P31947; | 4×GOL; | 6qhl | |
| Assess | ||||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521 |
Heteromer P31947; | 2×L3Y; | 6yow | |
| Assess | ||||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-123 |
Heteromer P31947; | 2×P7E; | 6ypy | |
| Assess | ||||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-037 |
Heteromer P31947; | 2×CL; 2×P6H; | 6ypl | |
| Assess | ||||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-028 |
Heteromer P31947; | 2×CL; 2×P5Q; | 6yp3 | |
| Assess | ||||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-025 |
Heteromer P31947; | 2×CL; 2×L3S; | 6yoy | |
| Assess | ||||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-033 |
Heteromer P31947; | 2×CL; 2×P6Z; | 6yp8 | |
| Assess | ||||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-011 |
Heteromer P31947; | 2×CL; 2×P5N; | 6yp2 | |
| Assess | ||||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-027 |
Heteromer P31947; | 2×CL; 2×L3V; 2×CA; 2×MG; | 6yox | |
| Assess | ||||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-129 |
Heteromer P31947; | 2×P7T; | 6yq2 | |
| Assess | ||||
| Crystal Structure of Brd4 Bromodomain 1 in Complex with Acetylated Rel Peptide |
Heteromer O60885; | 4kv1 | ||
| Assess | ||||
| Human SETD6 in complex with RelA Lys310 peptide |
Heteromer Q8TBK2; | 10×EDO; 1×SAM; | 3rc0 | |
| Assess | ||||
| Brd4 Bromodomain 2 in Complex with Acetylated Rel Peptide |
Heteromer O60885; | 1×DTT; | 4kv4 | |
| Assess | ||||
| 14-3-3 sigma with RelA/p65 binding site pS281 |
Heteromer P31947; | 6qhm | ||
| Assess | ||||
| Human SETD6 in complex with RelA Lys310 |
Heteromer Q8TBK2; | 1×SAM; 11×EDO; | 3qxy | |
| Assess | ||||
Homology models
| Oligo-state | QMEAN | Template | Range | Seq id (%) | Ligands |
|---|---|---|---|---|---|
| monomer | -0.26 | 2i9t.1.C | 97.44 | ||
| Assess | |||||
| monomer | 0.01 | 1ooa.1.B | 45.64 | ||
| Assess | |||||
| monomer | -2.59 | 2lww.1.B | 81.54 | ||
| Assess | |||||
Homology models built on isoform sequence
| Isoform | Oligo-state | Ligands | QMEAN | Template | Range | Seq id (%) |
|---|---|---|---|---|---|---|
| Isoform 2 | monomer | -0.47 | 2i9t.1.C | 95.60 | ||
| Assess | ||||||
| Isoform 2 | monomer | -0.01 | 1ooa.1.B | 44.76 | ||
| Assess | ||||||
| Isoform 2 | monomer | -2.01 | 1nfi.1.A | 98.00 | ||
| Assess | ||||||
| Isoform 2 | monomer | -2.84 | 5urn.1.B | 100.00 | ||
| Assess | ||||||
| Isoform 2 | monomer | -2.59 | 2lww.1.B | 81.54 | ||
| Assess | ||||||
| Isoform 3 | monomer | -0.88 | 2i9t.1.C | 97.34 | ||
| Assess | ||||||
| Isoform 3 | monomer | -0.10 | 1ooa.1.B | 45.85 | ||
| Assess | ||||||
| Isoform 3 | monomer | -1.96 | 1nfi.1.A | 99.66 | ||
| Assess | ||||||
| Isoform 3 | monomer | -2.84 | 5urn.1.B | 100.00 | ||
| Assess | ||||||
| Isoform 3 | monomer | -2.59 | 2lww.1.B | 81.54 | ||
| Assess | ||||||
| Isoform 4 | monomer | -0.11 | 2i9t.1.C | 97.41 | ||
| Assess | ||||||
| Isoform 4 | monomer | -1.96 | 1nfi.1.A | 98.99 | ||
| Assess | ||||||
| Isoform 4 | monomer | -2.84 | 5urn.1.B | 100.00 | ||
| Assess | ||||||
| Isoform 4 | monomer | -2.59 | 2lww.1.B | 81.54 | ||
| Assess | ||||||